Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 3,667 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Alvocidib (flavopiridol) and cytarabine (Ara-C), Alvocidib (flavopiridol)
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Clovis, California • Duarte, California • Los Angeles, California + 14 more
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Pomalidomide, Dexamethasone, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
22
States / cities
Mobile, Alabama • Santa Barbara, California • Denver, Colorado + 17 more
Conditions
Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, T-Cell Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cyclosporine, Cytarabine, Etoposide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Therapeutic Autologous Lymphocytes, Total-Body Irradiation
Procedure · Drug · Other + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2018
U.S. locations
4
States / cities
Salt Lake City, Utah • Seattle, Washington
Conditions
Solid Tumor
Interventions
Bevacizumab, Temozolomide, Vincristine, Irinotecan, Cefixime
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Relapsed/Refractory Aggressive B-Cell Lymphoma
Interventions
cemiplimab, odronextamab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • Grand Rapids, Michigan + 1 more
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Pemetrexed
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Leukemia
Interventions
Thalidomide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Pediatric Cancer, Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Soft Tissue Sarcomas, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumors
Interventions
Magnetic resonance high intensity focused ultrasound, Lyso-thermosensitive liposomal doxorubicin
Device · Drug
Lead sponsor
AeRang Kim
Other
Eligibility
Up to 30 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Solid Tumor
Interventions
IGM-7354
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
New Haven, Connecticut • Sarasota, Florida • Huntersville, North Carolina + 2 more
Conditions
Advanced Cancers, Melanoma
Interventions
MGN1703, Ipilimumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
cytarabine, deoxycytidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma
Interventions
Selinexor, Ixazomib, Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Neuroblastoma Recurrent
Interventions
DFMO, Bortezomib
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
Up to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
6
States / cities
Little Rock, Arkansas • Hartford, Connecticut • Orlando, Florida + 3 more
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
CD4+CD25+ regulatory T cells, allogeneic hematopoietic stem cell transplantation
Biological · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ziv-aflibercept
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
25 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Conditions
Non-Hodgkin's Lymphoma
Interventions
Obinutuzumab, Rituximab, Polatuzumab Vedotin, Venetoclax
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
10
States / cities
Tucson, Arizona • New Haven, Connecticut • Pembroke, Florida + 7 more
Conditions
Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
AFM11
Drug
Lead sponsor
Affimed GmbH
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Prexasertib, Mitoxantrone, Etoposide, Cytarabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Leukemia
Interventions
bryostatin 1, cladribine
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
3
States / cities
Detroit, Michigan • Grosse Pointe Woods, Michigan
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
ascorbic acid, arsenic trioxide, dexamethasone, thalidomide
Dietary Supplement · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
Interventions
arsenic trioxide, ascorbic acid, dexamethasone, thalidomide, anti-cytokine therapy, antiangiogenesis therapy, biological therapy, chemotherapy, drug resistance inhibition, growth factor antagonist therapy, non-specific immune-modulator therapy
Drug · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Lymphoma, Primary Effusion
Interventions
Daratumumab SC
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Multiple Myeloma
Interventions
Cevostamab, Tocilizumab, Pomalidomide, Daratumumab, Dexamethasone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 3 more
Conditions
Advanced Solid Tumors, Relapsed/Refractory Lymphoma
Interventions
Alisertib, Itraconazole
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
St Louis, Missouri • Oklahoma City, Oklahoma • Germantown, Tennessee + 1 more